查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
老年黃斑部病變 (AMD) 抗 VEGF 藥物的全球市場 - 產業趨勢與預測 (-2031)
市場調查報告書
商品編碼
1398926

老年黃斑部病變 (AMD) 抗 VEGF 藥物的全球市場 - 產業趨勢與預測 (-2031)

Global Age-Related Updated Macular Degeneration (AMD) Disease - ANTI VEGF Market - Industry Trends and Forecast to 2031
出版日期: | 出版商: Data Bridge Market Research | 英文 221 Pages | 商品交期: 請詢問到貨日

價格

全球老年黃斑部病變（AMD）抗VEGF市場規模將於2023年達到136.7702億美元，到2031年將達到229.519億美元，2024-2031年預測期間內複合年增長率為6.8%。

本報告針對全球老年黃斑部病變（AMD）抗VEGF市場進行研究分析，提供產業趨勢與預測、驅動與限制因素、公司動態等資訊。

目錄

第 1 章 簡介

第二章 市場區隔

第三章執行摘要

第 4 章重要注意事項

  • 佩斯特爾
  • 搬運工
  • 價格分析
  • 戰略舉措

第五章 監理框架

第六章市場概況

  • 促進者
    • 老年性黃斑部病變盛行率上升
    • 領先企業增加策略舉措
    • 管道產品增加
    • 老年人口增加
    • 年齡相關性黃斑部病變 (AMD) 的產品核准量增加
  • 抑制因素
    • 治療和手術費用高
    • 缺乏合格的專業人員
  • 機會
    • 加大研發力度
    • AMD 認知度和治療請求率提高
    • 新的治療報銷政策
  • 任務
    • 獲得治療的機會有限
    • 政府對產品的嚴格監管

第 7 章全球老年黃斑部病變 (AMD) 抗 VEGF 市場：按類型

  • 概述
  • 濕AMD
    • 劑量
    • 手術
  • 乾性AMD

第 8 章全球老年黃斑部病變 (AMD) 抗 VEGF 市場：依最終用戶分類

  • 概述
  • 醫院
  • 專科診所
  • 門診手術中心
  • 家庭醫療
  • 其他

第9章全球老年黃斑部病變（AMD）抗VEGF市場：按分銷管道

  • 概述
  • 零售
    • 醫院藥房
    • 零售藥店
    • 其他
  • 直接報價

第10章全球老年黃斑部病變（AMD）抗VEGF市場：按地區

  • 概述
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 俄羅斯
    • 意大利
    • 西班牙
    • 荷蘭
    • 瑞士
    • 波蘭
    • 土耳其
    • 奧地利
    • 匈牙利
    • 挪威
    • 愛爾蘭
    • 立陶宛
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 新加坡
    • 泰國
    • 印度尼西亞
    • 菲律賓
    • 馬來西亞
    • 越南
    • 亞太其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 秘魯
    • 南美洲其他地區
  • 中東/非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 以色列
    • 埃及
    • 科威特
    • 南非其他地區

第十一章全球老年黃斑部病變（AMD）抗 VEGF 市場：企業狀況

  • 公司股票分析：全球

第十二章北美年齡相關性黃斑部病變（AMD）抗VEGF市場：公司狀況

  • 公司股票分析：北美

第十三章歐洲年齡相關性黃斑部病變（AMD）抗 VEGF 市場：企業狀況

  • 公司股票分析：歐洲

第14章亞太地區老年黃斑部病變（AMD）抗VEGF市場：企業狀況

  • 公司股票分析：亞太地區

第15章SWOT分析

第十六章公司簡介

  • REGENERON PHARMACEUTICALS INC.
  • BAYER AG
  • GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD)
  • NOVARTIS AG
  • IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
  • ADVERUM BIOTECHNOLOGIES, INC.
  • BIOGEN
  • GENSIGHT BIOLOGICS
  • IONIS PHARMACEUTICALS
  • JOHNSON & JOHNSON SERVICES, INC.
  • KODIAK SCIENCES INC.
  • MEIRAGTX LIMITED
  • OCUGEN, INC.
  • OUTLOOK THERAPEUTICS, INC.
  • REGENXBIO INC.
  • SYLENTIS, S.A.

第十七章調查

第十八章 相關報告

The global age-related macular degeneration (AMD) disease - anti VEGF market is expected to reach USD 22,951.90 million by 2031 from USD 13,677.02 million in 2023, growing with a CAGR of 6.8% in the forecast period of 2024 to 2031.

Market Segmentation

Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales, Direct Tenders, and Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and rest of Middle East and Africa) - Industry Trends and Forecast to 2031.

Overview of Global Age-Related Macular Degeneration (AMD) Disease - ANTI VEGF Market Dynamics

  • Driver
  • Rising prevalence of age-related macular degeneration
  • Restraint
  • High-Cost of treatment and procedures
  • Opportunity
  • Increase in awareness and treatment seeking rate of AMD

Market Players

Some of the major market players operating in the global Age-Related Macular Degeneration (AMD) disease - anti VEGF market are listed below:

  • Regeneron Pharmaceuticals Inc. ()
  • Novartis AG
  • Bayer AG
  • IVERIC bio, Inc., An Astellas Company
  • Genentech, Inc. (A subsidiary of F. Hoffmann-La Roche Ltd)
  • Johnson & Johnson Services, Inc.
  • KODIAK SCIENCES INC.
  • Adverum Biotechnologies, Inc.
  • Biogen
  • Sylentis, S.A.
  • MeiraGTx Limited
  • Ionis Pharmaceuticals
  • Gensight Bilogics
  • OGUGEN, INC.
  • Outlook Therapeutics, Inc.
  • REGENXBIO Inc.

TABLE OF CONTENTS

1 INTRODUCTION 25

  • 1.1 OBJECTIVES OF THE STUDY 25
  • 1.2 MARKET DEFINITION 25
  • 1.3 OVERVIEW OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET 25
  • 1.4 LIMITATIONS 27
  • 1.5 MARKETS COVERED 27

2 MARKET SEGMENTATION 29

  • 2.1 MARKETS COVERED 29
  • 2.2 GEOGRAPHICAL SCOPE 30
  • 2.3 YEARS CONSIDERED FOR THE STUDY 31
  • 2.4 CURRENCY AND PRICING 31
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
  • 2.6 MULTIVARIATE MODELLING 35
  • 2.7 TYPE LIFELINE CURVE 36
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
  • 2.9 DBMR MARKET POSITION GRID 38
  • 2.10 MARKET END USER COVERAGE GRID 39
  • 2.11 VENDOR SHARE ANALYSIS 40
  • 2.12 SECONDARY SOURCES 41
  • 2.13 ASSUMPTIONS 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHTS 45

  • 4.1 PESTEL 47
  • 4.2 PORTERS_ 48
  • 4.3 PRICING ANALYSIS 49
  • 4.4 STRATEGIC INITIATIVES 50

5 REGULATORY FRAMEWORK 51

6 MARKET OVERVIEW 54

  • 6.1 DRIVERS 56
    • 6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 56
    • 6.1.2 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 56
    • 6.1.3 INCREASE IN PIPELINE PRODUCTS 57
    • 6.1.4 INCREASING GERIATRIC POPULATION 58
    • 6.1.5 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 59
  • 6.2 RESTRAINTS 59
    • 6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 59
    • 6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 60
  • 6.3 OPPORTUNITIES 60
    • 6.3.1 INCREASING RESEARCH AND DEVELOPMENT 60
    • 6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 61
    • 6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 61
  • 6.4 CHALLENGES 61
    • 6.4.1 LIMITED ACCESS TO TREATMENT 61
    • 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 62

7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE 63

  • 7.1 OVERVIEW 64
  • 7.2 WET AMD 67
    • 7.2.1 MEDICATIONS 68
      • 7.2.1.1 ANTI-VEGF THERAPY 68
      • 7.2.1.2 OTHERS 68
    • 7.2.2 SURGERY 68
  • 7.3 DRY AMD 69

8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER 70

  • 8.1 OVERVIEW 71
  • 8.2 HOSPITALS 74
  • 8.3 SPECIALTY CLINICS 75
  • 8.4 AMBULATORY SURGICAL CENTERS 75
  • 8.5 HOME HEALTHCARE 76
  • 8.6 OTHERS 76

9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL 77

  • 9.1 OVERVIEW 78
  • 9.2 RETAIL SALES 81
    • 9.2.1 HOSPITAL PHARMACIES 82
    • 9.2.2 RETAIL PHARMACIES 82
    • 9.2.3 OTHERS 82
  • 9.3 DIRECT TENDER 83

10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION 84

  • 10.1 OVERVIEW 85
  • 10.2 NORTH AMERICA 88
    • 10.2.1 U.S. 90
    • 10.2.2 CANADA 92
    • 10.2.3 MEXICO 94
  • 10.3 EUROPE 96
    • 10.3.1 GERMANY 99
    • 10.3.2 FRANCE 101
    • 10.3.3 U.K. 103
    • 10.3.4 RUSSIA 105
    • 10.3.5 ITALY 107
    • 10.3.6 SPAIN 109
    • 10.3.7 NETHERLANDS 111
    • 10.3.8 SWITZERLAND 113
    • 10.3.9 POLAND 115
    • 10.3.10 TURKEY 117
    • 10.3.11 AUSTRIA 119
    • 10.3.12 HUNGARY 121
    • 10.3.13 NORWAY 123
    • 10.3.14 IRELAND 125
    • 10.3.15 LITHUANIA 127
    • 10.3.16 REST OF EUROPE 129
  • 10.4 ASIA-PACIFIC 130
    • 10.4.1 CHINA 133
    • 10.4.2 JAPAN 135
    • 10.4.3 INDIA 137
    • 10.4.4 SOUTH KOREA 139
    • 10.4.5 AUSTRALIA 141
    • 10.4.6 SINGAPORE 143
    • 10.4.7 THAILAND 145
    • 10.4.8 INDONESIA 147
    • 10.4.9 PHILIPPINES 149
    • 10.4.10 MALAYSIA 151
    • 10.4.11 VIETNAM 153
    • 10.4.12 REST OF ASIA-PACIFIC 155 
  • 10.5 SOUTH AMERICA 156
    • 10.5.1 BRAZIL 158
    • 10.5.2 ARGENTINA 160
    • 10.5.3 PERU 162
    • 10.5.4 REST OF SOUTH AMERICA 164
  • 10.6 MIDDLE EAST AND AFRICA 165
    • 10.6.1 SOUTH AFRICA 167
    • 10.6.2 SAUDI ARABIA 169
    • 10.6.3 U.A.E. 171
    • 10.6.4 ISRAEL 173
    • 10.6.5 EGYPT 175
    • 10.6.6 KUWAIT 177
    • 10.6.7 REST OF SOUTH AFRICA 179

11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE 180

  • 11.1 COMPANY SHARE ANALYSIS: GLOBAL 180

12 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE 181

  • 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 181

13 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE 182

  • 13.1 COMPANY SHARE ANALYSIS: EUROPE 182

14 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE 183

  • 14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 183

15 SWOT ANALYSIS 184

16 COMPANY PROFILE 185

  • 16.1 REGENERON PHARMACEUTICALS INC. 185
    • 16.1.1 COMPANY SNAPSHOT 185
    • 16.1.2 REVENUE ANALYSIS 186
    • 16.1.3 COMPANY SHARE ANALYSIS 186
    • 16.1.4 PRODUCT PORTFOLIO 187
    • 16.1.5 RECENT DEVELOPMENTS 187 
  • 16.2 BAYER AG 188
    • 16.2.1 COMPANY SNAPSHOT 188
    • 16.2.2 REVENUE ANALYSIS 188
    • 16.2.3 COMPANY SHARE ANALYSIS 189
    • 16.2.4 PRODUCT PORTFOLIO 189
    • 16.2.5 RECENT DEVELOPMENT 190
  • 16.3 GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD) 191
    • 16.3.1 COMPANY SNAPSHOT 191
    • 16.3.2 COMPANY SHARE ANALYSIS 191
    • 16.3.3 PRODUCT PORTFOLIO 192
    • 16.3.4 RECENT DEVELOPMENT 192
  • 16.4 NOVARTIS AG 193
    • 16.4.1 COMPANY SNAPSHOT 193
    • 16.4.2 REVENUE ANALYSIS 193
    • 16.4.3 COMPANY SHARE ANALYSIS 194
    • 16.4.4 PRODUCT PORTFOLIO 194
    • 16.4.5 RECENT DEVELOPMENTS 195
      • 16.4.5.1 AGREEMENT 195
  • 16.5 IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.) 196
    • 16.5.1 COMPANY SNAPSHOT 196
    • 16.5.2 REVENUE ANALYSIS 196
    • 16.5.3 COMPANY SHARE ANALYSIS 197
    • 16.5.4 PRODUCT PORTFOLIO 197
    • 16.5.5 RECENT DEVELOPMENT 198
  • 16.6 ADVERUM BIOTECHNOLOGIES, INC. 199
    • 16.6.1 COMPANY SNAPSHOT 199
    • 16.6.2 PRODUCT PORTFOLIO 199
    • 16.6.3 RECENT DEVELOPMENT 200
  • 16.7 BIOGEN 201
    • 16.7.1 COMPANY SNAPSHOT 201
    • 16.7.2 PRODUCT PORTFOLIO 201
    • 16.7.3 RECENT DEVELOPMENT 201
  • 16.8 GENSIGHT BIOLOGICS 202
    • 16.8.1 COMPANY SNAPSHOT 202
    • 16.8.2 REVENUE ANALYSIS 202
    • 16.8.3 PRODUCT PORTFOLIO 203
    • 16.8.4 RECENT DEVELOPMENTS 203 
  • 16.9 IONIS PHARMACEUTICALS 204
    • 16.9.1 COMPANY SNAPSHOT 204
    • 16.9.2 REVENUE ANALYSIS 204
    • 16.9.3 PRODUCT PORTFOLIO 205
    • 16.9.4 RECENT DEVELOPMENTS 205
  • 16.10 JOHNSON &JOHNSON SERVICES, INC. 206
    • 16.10.1 COMPANY SNAPSHOT 206
    • 16.10.2 REVENUE ANALYSIS 206
    • 16.10.3 PRODUCT PORTFOLIO 207
    • 16.10.4 RECENT DEVELOPMENTS 207
  • 16.11 KODIAK SCIENCES INC. 209
    • 16.11.1 COMPANY SNAPSHOT 209
    • 16.11.2 PRODUCT PORTFOLIO 209
    • 16.11.3 RECENT DEVELOPMENTS 209
  • 16.12 MEIRAGTX LIMITED 210
    • 16.12.1 COMPANY SNAPSHOT 210
    • 16.12.2 PRODUCT PORTFOLIO 210
    • 16.12.3 RECENT DEVELOPMENTS 210
  • 16.13 OCUGEN, INC. 212
    • 16.13.1 COMPANY SNAPSHOT 212
    • 16.13.2 PRODUCT PORTFOLIO 212
    • 16.13.3 RECENT DEVELOPMENTS 213
  • 16.14 OUTLOOK THERAPEUTICS, INC. 214
    • 16.14.1 COMPANY SNAPSHOT 214
    • 16.14.2 PRODUCT PORTFOLIO 214
    • 16.14.3 RECENT DEVELOPMENT 214
  • 16.15 REGENXBIO INC. 215
    • 16.15.1 COMPANY SNAPSHOT 215
    • 16.15.2 PRODUCT PORTFOLIO 215
    • 16.15.3 RECENT DEVELOPMENTS 216
  • 16.16 SYLENTIS, S.A. 217
    • 16.16.1 COMPANY SNAPSHOT 217
    • 16.16.2 PRODUCT PORTFOLIO 217
    • 16.16.3 RECENT DEVELOPMENT 217

17 QUESTIONNAIRE 218

18 RELATED REPORTS 221

LIST OF TABLES

  • TABLE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 67
  • TABLE 2 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 67
  • TABLE 3 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 67
  • TABLE 4 GLOBAL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 68
  • TABLE 5 GLOBAL DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 69
  • TABLE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 74
  • TABLE 7 GLOBAL HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF, BY REGION, 2022-2031 (USD MILLION) 74
  • TABLE 8 GLOBAL SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 75
  • TABLE 9 GLOBAL AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 75
  • TABLE 10 GLOBAL HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 76
  • TABLE 11 GLOBAL OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 76
  • TABLE 12 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 81
  • TABLE 13 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 81
  • TABLE 14 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 82
  • TABLE 15 GLOBAL DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 83
  • TABLE 16 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 87
  • TABLE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 88
  • TABLE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 88
  • TABLE 19 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 88
  • TABLE 20 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 88
  • TABLE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 89
  • TABLE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 89
  • TABLE 23 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 89
  • TABLE 24 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
  • TABLE 25 U.S. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
  • TABLE 26 U.S. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
  • TABLE 27 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 90
  • TABLE 28 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 91
  • TABLE 29 U.S. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 91
  • TABLE 30 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 92
  • TABLE 31 CANADA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 92
  • TABLE 32 CANADA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 92
  • TABLE 33 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 92
  • TABLE 34 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 93
  • TABLE 35 CANADA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 93
  • TABLE 36 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
  • TABLE 37 MEXICO WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
  • TABLE 38 MEXICO MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
  • TABLE 39 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 94
  • TABLE 40 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 95
  • TABLE 41 MEXICO RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 95
  • TABLE 42 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 96
  • TABLE 43 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 97
  • TABLE 44 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 97
  • TABLE 45 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 97
  • TABLE 46 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 98
  • TABLE 47 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 98
  • TABLE 48 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 98
  • TABLE 49 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 99
  • TABLE 50 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 99
  • TABLE 51 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 99
  • TABLE 52 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 100
  • TABLE 53 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 100
  • TABLE 54 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 100
  • TABLE 55 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 101
  • TABLE 56 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 101
  • TABLE 57 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 101
  • TABLE 58 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 102
  • TABLE 59 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 102
  • TABLE 60 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 102
  • TABLE 61 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 103
  • TABLE 62 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 103
  • TABLE 63 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 103
  • TABLE 64 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 104
  • TABLE 65 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 104
  • TABLE 66 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 104
  • TABLE 67 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 105
  • TABLE 68 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 105
  • TABLE 69 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 105
  • TABLE 70 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 106
  • TABLE 71 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 106
  • TABLE 72 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 106
  • TABLE 73 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 107
  • TABLE 74 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 107
  • TABLE 75 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 107
  • TABLE 76 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 108
  • TABLE 77 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 108
  • TABLE 78 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 108
  • TABLE 79 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 109
  • TABLE 80 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 109
  • TABLE 81 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 109
  • TABLE 82 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 110
  • TABLE 83 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 110
  • TABLE 84 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 110
  • TABLE 85 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 111
  • TABLE 86 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 111
  • TABLE 87 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 111
  • TABLE 88 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 112
  • TABLE 89 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 112
  • TABLE 90 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 112
  • TABLE 91 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 113
  • TABLE 92 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 113
  • TABLE 93 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 113
  • TABLE 94 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 114
  • TABLE 95 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 114
  • TABLE 96 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 114
  • TABLE 97 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 115
  • TABLE 98 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 115
  • TABLE 99 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 115
  • TABLE 100 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 116
  • TABLE 101 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 116
  • TABLE 102 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 116
  • TABLE 103 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 117
  • TABLE 104 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 117
  • TABLE 105 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 117
  • TABLE 106 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 118
  • TABLE 107 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 118
  • TABLE 108 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 118
  • TABLE 109 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 119
  • TABLE 110 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 119
  • TABLE 111 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 119
  • TABLE 112 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 120
  • TABLE 113 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 120
  • TABLE 114 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 120
  • TABLE 115 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 121
  • TABLE 116 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 121
  • TABLE 117 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 121
  • TABLE 118 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 122
  • TABLE 119 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 122
  • TABLE 120 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 122
  • TABLE 121 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 123
  • TABLE 122 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 123
  • TABLE 123 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 123
  • TABLE 124 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 124
  • TABLE 125 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 124
  • TABLE 126 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 124
  • TABLE 127 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 125
  • TABLE 128 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 125
  • TABLE 129 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 125
  • TABLE 130 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 126
  • TABLE 131 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 126
  • TABLE 132 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 126
  • TABLE 133 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 127
  • TABLE 134 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 127
  • TABLE 135 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 127
  • TABLE 136 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 128
  • TABLE 137 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 128
  • TABLE 138 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 128
  • TABLE 139 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 129
  • TABLE 140 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 130
  • TABLE 141 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 142 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 143 ASIA-PACIFIC MEDICATION IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 144 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 145 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 132
  • TABLE 146 ASIA-PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 132
  • TABLE 147 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 148 CHINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 149 CHINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 150 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 134
  • TABLE 151 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 134
  • TABLE 152 CHINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 134
  • TABLE 153 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 135
  • TABLE 154 JAPAN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 135
  • TABLE 155 JAPAN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 135
  • TABLE 156 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 136
  • TABLE 157 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 136
  • TABLE 158 JAPAN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 136
  • TABLE 159 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 160 INDIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 161 INDIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 162 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 138
  • TABLE 163 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 138
  • TABLE 164 INDIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 138
  • TABLE 165 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 166 SOUTH KOREA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 167 SOUTH KOREA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 168 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 140
  • TABLE 169 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 140
  • TABLE 170 SOUTH KOREA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 140
  • TABLE 171 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 141
  • TABLE 172 AUSTRALIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 141
  • TABLE 173 AUSTRALIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 141
  • TABLE 174 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 142
  • TABLE 175 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 142
  • TABLE 176 AUSTRALIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 142
  • TABLE 177 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 178 SINGAPORE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 179 SINGAPORE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 180 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 144
  • TABLE 181 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 144
  • TABLE 182 SINGAPORE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 144
  • TABLE 183 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 145
  • TABLE 184 THAILAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 145
  • TABLE 185 THAILAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 145
  • TABLE 186 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 146
  • TABLE 187 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 146
  • TABLE 188 THAILAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 146
  • TABLE 189 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 190 INDONESIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 191 INDONESIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 192 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 148
  • TABLE 193 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 148
  • TABLE 194 INDONESIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 148
  • TABLE 195 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 196 PHILIPPINES WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 197 PHILIPPINES MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 198 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 150
  • TABLE 199 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 150
  • TABLE 200 PHILIPPINES RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 150
  • TABLE 201 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 151
  • TABLE 202 MALAYSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 151
  • TABLE 203 MALAYSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 151
  • TABLE 204 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 152
  • TABLE 205 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 152
  • TABLE 206 MALAYSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 152
  • TABLE 207 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 208 VIETNAM WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 209 VIETNAM MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 210 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 154
  • TABLE 211 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 154
  • TABLE 212 VIETNAM RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 154
  • TABLE 213 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 155
  • TABLE 214 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 156
  • TABLE 215 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 156
  • TABLE 216 SOUTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 156
  • TABLE 217 SOUTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 218 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 157
  • TABLE 219 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 157
  • TABLE 220 SOUTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 157
  • TABLE 221 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 222 BRAZIL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 223 BRAZIL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 224 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 158
  • TABLE 225 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 159
  • TABLE 226 BRAZIL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 159
  • TABLE 227 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 228 ARGENTINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 229 ARGENTINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 230 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 160
  • TABLE 231 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 161
  • TABLE 232 ARGENTINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 161
  • TABLE 233 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 234 PERU WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 235 PERU MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 236 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 162
  • TABLE 237 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 163
  • TABLE 238 PERU RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 163
  • TABLE 239 REST OF SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 240 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 165
  • TABLE 241 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 242 MIDDLE EAST AND AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 243 MIDDLE EAST AND AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 244 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 166
  • TABLE 245 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 166
  • TABLE 246 MIDDLE EAST AND AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 166
  • TABLE 247 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 248 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 249 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 250 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 167
  • TABLE 251 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 168
  • TABLE 252 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 168
  • TABLE 253 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 254 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 255 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 256 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 169
  • TABLE 257 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 170
  • TABLE 258 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 170
  • TABLE 259 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 260 U.A.E. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 261 U.A.E. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 262 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 171
  • TABLE 263 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 172
  • TABLE 264 U.A.E. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 172
  • TABLE 265 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 266 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 267 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 268 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 173
  • TABLE 269 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 174
  • TABLE 270 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 174
  • TABLE 271 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 272 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 273 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 274 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 175
  • TABLE 275 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 176
  • TABLE 276 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 176
  • TABLE 277 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 278 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 279 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 280 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 177
  • TABLE 281 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 178
  • TABLE 282 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 178
  • TABLE 283 REST OF SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 179

LIST OF FIGURES

  • FIGURE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION 29
  • FIGURE 2 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DATA TRIANGULATION 32
  • FIGURE 3 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DROC ANALYSIS 33
  • FIGURE 4 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 34
  • FIGURE 5 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: COMPANY RESEARCH ANALYSIS 34
  • FIGURE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MULTIVARIATE MODELLING 35
  • FIGURE 7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: INTERVIEW DEMOGRAPHICS 37
  • FIGURE 8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DBMR MARKET POSITION GRID 38
  • FIGURE 9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: END USER COVERAGE GRID 39
  • FIGURE 10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: VENDOR SHARE ANALYSIS 40
  • FIGURE 11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION 43
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST RATE IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 44
  • FIGURE 13 AN INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE GROWTH OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 45
  • FIGURE 14 WET AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN 2023 AND 2031 45
  • FIGURE 15 EUROPE IS THE FASTEST-GROWING MARKET IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 46
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET 55
  • FIGURE 17 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2023 64
  • FIGURE 18 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2024-2031 (USD MILLION) 65
  • FIGURE 19 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, CAGR (2024-2031) 65
  • FIGURE 20 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, LIFELINE CURVE 66
  • FIGURE 21 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2023 71
  • FIGURE 22 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2024-2031 (USD MILLION) 72
  • FIGURE 23 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, CAGR (2024-2031) 72
  • FIGURE 24 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, LIFELINE CURVE 73
  • FIGURE 25 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2023 78
  • FIGURE 26 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 79
  • FIGURE 27 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 79
  • FIGURE 28 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 80
  • FIGURE 29 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SNAPSHOT (2023) 86
  • FIGURE 30 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%) 180
  • FIGURE 31 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%) 181
  • FIGURE 32 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%) 182
  • FIGURE 33 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%) 183